CRNX - Crinetics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.364B

Cash

264.5M

Avg Qtr Burn

-40.03M

Short % of Float

8.62%

Insider Ownership

2.42%

Institutional Own.

-

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Paltusotine (SST2 agonist) Details Acromegaly Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Paltusotine (SST2 agonist) Details Neuroendocrine tumor, Carcinoid syndrome	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CRN04894 (ACTH antagonist) Details Congenital adrenal hyperplasia, Cushing’s syndrome	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CRN04777 (SST5 agonist) Details Hyperinsulinism	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.